Search

everythinglearnresearchcommunity

for

Search:↓

Targeted immunotherapies may offer better treatment for alopecia areata by controlling inflammation and immune responses.

Infliximab can trigger lupus-like symptoms in Crohn's disease patients.

Hepatitis B virus exposure may be linked to increased risk of alopecia areata.

Some treatments for inflammatory bowel disease can cause skin problems like rashes and melanoma.

Anti-Desmocollin 3 antibodies can cause atypical pemphigus symptoms.

Live imaging helps us understand skin immune responses and develop treatments.

Hair dye may trigger anti-GBM disease relapse, and rituximab can help manage it.

A patient's grey hair regained color during treatment with adalimumab.

Dupilumab for skin problems might reactivate hair loss in some patients.

T cells with memory features grow in number and gather around hair follicles when there are not enough immune cells.

Targeting immune tolerance issues in Alopecia Areata could restore hair growth and maintain remission.

Immune cells might contribute to hair loss caused by a specific mutation.

Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.

Innate lymphoid cells type 1 may contribute to alopecia areata by damaging hair follicles.

Cancer treatments often cause skin, nail, and hair problems.

Mogamulizumab can cause hair loss and skin rashes.

Nirmatrelvir/Ritonavir treatment may lead to a weaker immune response to COVID-19, but doesn't affect the chance of rebound.

A patient with Ivemark syndrome developed mixed type vitiligo after a hepatitis C infection, showing different treatment responses and immune cell involvement in the skin.

Atopy and altered T cell functions contribute to Alopecia Areata.

Tph cells are linked to the severity of systemic lupus erythematosus.

Damaging mutations in NFKB2 cause a severe and distinct form of primary immunodeficiency with early-onset and often ACTH-deficiency.

Increased Treg cells and IL-10 may help quick recovery in acute diffuse and total alopecia.

Modified superoxide dismutase may trigger an autoimmune response in alopecia areata.

COVID-19 mRNA vaccines may increase the risk of flare-ups in certain inflammatory diseases.

Chronic inflammatory skin diseases are caused by disrupted interactions between skin cells and immune cells.

HHV-6 reactivation may be linked to psychiatric disorders and can improve with antiviral treatment.

A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.

Most skin rashes in rheumatoid arthritis patients were not caused by their medication, and careful evaluation allowed most to keep taking their beneficial treatment.

Various medications and vaccines can cause serious side effects.